首页> 外文期刊>International Journal of General Medicine >Inotropes do not increase mortality in advanced heart failure
【24h】

Inotropes do not increase mortality in advanced heart failure

机译:正性肌力药不会增加晚期心力衰竭的死亡率

获取原文
           

摘要

Abstract: Inotrope use is one of the most controversial topics in the management of heart failure. While the heart failure community utilizes them and recognizes the state of inotrope dependency, retrospective analyses and registry data have overwhelmingly suggested high mortality, which is logically to be expected given the advanced disease states of those requiring their use. Currently, there is a relative paucity of randomized control trials due to the ethical dilemma of creating control groups by withholding inotropes from patients who require them. Nonetheless, results of such trials have been mixed. Many were also performed with agents no longer in use, on patients without an indication for inotropes, or at a time before automatic cardio-defibrillators were recommended for primary prevention. Thus, their results may not be generalizable to current clinical practice. In this review, we discuss current indications for inotrope use, specifically dobutamine and milrinone, depicting their mechanisms of action, delineating their patterns of use in clinical practice, defining the state of inotrope dependency, and ultimately examining the literature to ascertain whether evidence is sufficient to support the current view that these agents increase mortality in patients with heart failure. Our conclusion is that the evidence is insufficient to link inotropes and increased mortality in low output heart failure.
机译:摘要:使用Introtrope是心力衰竭治疗中最具争议的主题之一。当心力衰竭社区利用它们并认识到inotrope依赖的状态时,回顾性分析和注册表数据已绝大多数显示出高死亡率,考虑到需要使用它们的患者的晚期疾病,这在逻辑上是可以预期的。目前,由于在伦理上难以通过从需要治疗的患者中禁用正性肌力药来建立对照组,因此在随机对照试验中相对较少。尽管如此,这种试验的结果好坏参半。在不再使用正性肌力药的患者中,或在推荐使用自动心脏除颤器进行一级预防之前,也对许多患者使用了不再使用的药物。因此,其结果可能无法推广到当前的临床实践。在这篇综述中,我们讨论了使用Inotrope的适应症,特别是多巴酚丁胺和米力农,描述了它们的作用机理,描述了它们在临床实践中的使用模式,定义了Inotrope的依赖状态,并最终研究了文献以确定证据是否足够支持目前的观点,即这些药物会增加心力衰竭患者的死亡率。我们的结论是,证据不足以将正性肌力药和低输出心力衰竭的死亡率增加联系起来。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号